Production (Stage)
LAVA Therapeutics N.V.
LVTX
$1.32
$0.021.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.37% | 67.71% | -48.20% | -1,264.47% | 90.49% |
| Total Depreciation and Amortization | 148.64% | -203.77% | -7.02% | 58.33% | 145.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -359.82% | -146.91% | 1,274.32% | -168.54% | -86.87% |
| Change in Net Operating Assets | -195.91% | 190.87% | 1,080.45% | 79.41% | 90.90% |
| Cash from Operations | -728.83% | 83.72% | -2.93% | -894.54% | 92.84% |
| Capital Expenditure | -- | 100.00% | -- | -- | -2,200.00% |
| Sale of Property, Plant, and Equipment | -- | -400.00% | -33.33% | -96.63% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 38.10% | 2,245.51% | 39.29% | -46.50% | 107.23% |
| Cash from Investing | 38.17% | 2,354.36% | 31.86% | -51.15% | 107.99% |
| Total Debt Issued | -- | -- | -300.78% | -- | -- |
| Total Debt Repaid | -- | -85.59% | 21.28% | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -88.24% | 112.50% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 44.02% | -7,460.00% | -37.50% | -98.91% |
| Foreign Exchange rate Adjustments | 187.54% | -405.61% | 801.64% | 93.24% | -169.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -42.14% | 199.13% | -0.27% | -675.96% | 94.34% |